Avonex injection for treatment of relapsing forms of multiple sclerosis in adults

Avonex is an injectable medicine containing interferon beta-1a used to treat adults with relapsing forms of multiple sclerosis (MS). It helps manage symptoms in relapsing-remitting MS, clinically isolated syndrome, and active secondary progressive MS by modifying the disease course.

Avonex is approved for the treatment of relapsing forms of multiple sclerosis (MS) in adults. This includes patients diagnosed with clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS.

interferon beta-1a

Avonex contains interferon beta-1a, a protein that modulates the immune system’s activity. It helps reduce inflammation and immune system attacks on nerve cells in the central nervous system, which are characteristic of multiple sclerosis.

Avonex is given as an intramuscular injection once weekly at a recommended dose of 30 micrograms.

To reduce flu-like symptoms at the start of treatment, dosing may begin at 7.5 micrograms once a week and increase by 7.5 micrograms each week over 3 weeks until reaching the full 30 microgram dose (week 1: 7.5 mcg; week 2: 15 mcg; week 3: 22.5 mcg; week 4 onward: 30 mcg).

The first injection should be supervised by a qualified healthcare professional. Patients or caregivers should be trained in proper intramuscular injection technique if self-administering. Injection sites should be rotated to avoid skin reactions, and the injection site should be inspected a few hours after dosing for redness or swelling.

Concurrent use of analgesics or antipyretics on treatment days may help reduce flu-like symptoms.

Avonex is available in single-dose prefilled syringes or prefilled autoinjectors. Needles must not be reused, and safe disposal procedures should be followed.

Avonex is contraindicated in patients with a known hypersensitivity to interferon beta, albumin (for the lyophilized formulation), or any component of the formulation.

• Depression and Suicide Risk: Depression, suicidal thoughts, and psychosis have occurred with Avonex. Patients should report symptoms promptly; consider stopping treatment if severe psychiatric symptoms develop.
• Hepatic Injury: Severe liver damage, including liver failure, has been reported. Liver function tests should be monitored periodically. Use caution when combined with other hepatotoxic agents.
• Allergic Reactions: Anaphylaxis and other allergic reactions may occur. Discontinue if these develop.
• Injection Site Reactions: Injection site pain, inflammation, necrosis, abscess, and cellulitis have been reported. Avoid injecting into irritated or damaged skin. If necrosis occurs, avoid the affected area until healed and consider discontinuation if multiple sites are involved.
• Congestive Heart Failure: Monitor patients with existing heart failure for worsening symptoms during treatment.
• Blood Cell Counts: Decreased blood cell counts including rare cases of pancytopenia and thrombocytopenia have occurred. Monitor complete blood counts.
• Thrombotic Microangiopathy: Serious blood vessel disorders including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome have been reported; discontinue Avonex if these occur.
• Pulmonary Arterial Hypertension: Cases have been reported, sometimes requiring hospitalization or lung transplant. Assess patients with unexplained respiratory symptoms and discontinue treatment if diagnosed.
• Autoimmune Disorders: New autoimmune diseases such as thyroid dysfunction or autoimmune hepatitis may develop; consider stopping treatment.
• Seizures: Seizures have been associated with Avonex; monitor and evaluate as needed.

The most common side effects include flu-like symptoms such as chills, fever, muscle aches, and fatigue occurring shortly after injection. These usually last about a day and often decrease over time.

In clinical studies, other frequently reported adverse reactions (more than 5% higher vs placebo) included headache, pain, asthenia, nausea, injection site pain and inflammation, respiratory infections, and urinary tract infections.

Serious but less common side effects include depression, injection site necrosis, liver injury, allergic reactions, blood count abnormalities, heart failure exacerbation, thrombotic microangiopathy, pulmonary hypertension, seizures, and autoimmune disorders.

Use caution when combining Avonex with other medications known to cause liver injury, as concurrent use may increase hepatic risks.

No pregnancy or lactation information is provided in the supplied evidence.

The supplied information does not include specific details on overdose symptoms or management for Avonex.

Store Avonex as indicated on the packaging; inspect the solution for particulate matter and discoloration before use. Do not use if solution is discolored or contains particles.